KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Shares Outstanding (Weighted Average) (2016 - 2026)

Moderna (MRNA) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $395.0 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 2.33% year-over-year to $395.0 million; the TTM value through Mar 2026 reached $395.0 million, up 2.33%, while the annual FY2025 figure was $389.0 million, 1.3% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $395.0 million in Q1 2026 for Moderna, up from $389.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $402.0 million in Q1 2022 and bottomed at $382.0 million in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $388.4 million, with a median of $386.0 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Weighted Average) fell 4.01% in 2023 and then grew 2.33% in 2026.
  • Moderna's Shares Outstanding (Weighted Average) stood at $394.0 million in 2022, then decreased by 3.05% to $382.0 million in 2023, then grew by 0.52% to $384.0 million in 2024, then increased by 1.3% to $389.0 million in 2025, then increased by 1.54% to $395.0 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $395.0 million, $389.0 million, and $388.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.